PURPOSE: To compare urinary, bowel, and sexual health-related quality-of-life (HRQOL) changes due to @entity1168 ( @entity1168 ) brachytherapy, low-dose-rate (LDR) brachytherapy, or intensity-modulated radiation therapy (IMRT) monotherapy for @entity263 . METHODS AND MATERIALS: Between January 2002 and September 2013, 413 low-risk or favorable intermediate-risk @entity263 @entity1 were treated with @entity1168 brachytherapy monotherapy to 2700-2800  cGy in two fractions (n  = 85), @entity1496 -125 LDR brachytherapy monotherapy to 14,500  cGy in one fraction (n  = 249), or IMRT monotherapy to 7400-8100  cGy in 37-45 fractions (n  = 79) without pelvic lymph node irradiation. No @entity342 deprivation therapy was given. @entity1 used an international prostate symptoms score questionnaire, an expanded @entity263 index composite-26 bowel questionnaire, and a sexual health inventory for @entity1 questionnaire to assess their urinary, bowel, and sexual HRQOL, respectively, pretreatment and at 1, 3, 6, 9, 12, and 18  months posttreatment. RESULTS: Median follow-up was 32  months. @entity1168 brachytherapy and IMRT @entity1 had significantly less deterioration in their urinary HRQOL than LDR brachytherapy @entity1 at 1 and 3  months after irradiation. The only significant decrease in bowel HRQOL between the groups was seen 18  months after treatment, at which point IMRT @entity1 had a slight, but significant, @entity1744 compared with @entity1168 and LDR brachytherapy @entity1 . @entity1168 brachytherapy @entity1 had worse sexual HRQOL than both LDR brachytherapy and IMRT @entity1 after treatment. CONCLUSIONS: IMRT and @entity1168 brachytherapy cause less severe acute worsening of urinary HRQOL than LDR brachytherapy. However, IMRT causes a slight, but significant, @entity1744 compared with @entity1168 and LDR brachytherapy.

Health-related quality-of-life changes due to @entity1168 brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men'] @entity1496 :: ('MESH:D007455', 'Chemical') :: ['iodine'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity1744 :: ('MESH:D043183', 'Disease') :: ['worsening of  bowel HRQOL', 'deterioration in their bowel HRQOL'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['HDR', 'high-dose-rate']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
